The effects of a herbal medicine (Mao-to) in patients with chronic hepatitis C after injection of IFN-β

Phytomedicine

Volumn 11, Issue 1, 2004, Pages 5-10

  Kainuma, M ^a   Sakai, S ^a   Sekiya, N ^a   Mantani, N ^b   Ogata, N ^a   Shimada, Y ^a   Terasawa, K ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Herbal medicine; IFN ; IL 1ra; IL 6; Mao to

Indexed keywords

ARMENICAE CORTEX EXTRACT; BETA INTERFERON; CINNAMOMI CORTEX EXTRACT; CYTOKINE; EPHEDRA HERBA EXTRACT; GLYCYRRHIZAE RADIX EXTRACT; HERBACEOUS AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAO TO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BODY TEMPERATURE; CHILL; CHRONIC HEPATITIS; CINNAMON; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FLU LIKE SYNDROME; GLYCYRRHIZA; HEADACHE; HEPATITIS C; HUMAN; MALAISE; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; THIRST; THORAX PAIN; VOMITING;

CINNAMOMUM VERUM; EPHEDRA; GLYCYRRHIZA; GYMNOMYZA SAMOENSIS; HEPATITIS C VIRUS;

EID: 1042280175     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1078/0944-7113-00344     Document Type: Article

References (20)

1. Arend WP (1991) Interleukin-1 receptor antagonist. A new member of the interleukin-1 family. J Clin Invest 88: 1445-1451
2. Dinarell CA, Thompson RC (1991) Blocking IL-1: interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 12: 404-410
3. Dusheiko G (1997). Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 (Suppl. 1): 112-121
4. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE (1998) Local and systemic cytokine response during experimental human influenza A virus infection. J Clin Invest 101: 643-649
5. Itoh Y, Okanoue T, Sakamoto S, Nishioji K, Yasui K, Sakamoto M, Kashima K (1995) Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon. Dig Dis Sci 40: 2423-2430
6. Jordan M, Otterness IG, NG R, GESSNER A, Rollinghoff M, Beusher HU (1995) Neutralization of endogenous IL-6 suppresses induction of IL-1 receptor antagonist. J Immunol 154: 4081-4090
7. Kainuma M, Hayashi J, Sakai S, Imai K, Mantani N, Kohta K, Mitsuma T, Shimada Y, Kashiwagi S, Terasawa K (2002) The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C. Am J Chin Med 30: 355-367
8. Kainuma M, Ogata N, Kogure T, Kohta K, Hattori N, Mitsuma T, Terasawa K (2002) The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-β for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine 9: 365-372
9. Kishihara Y, Hayashi J, Yoshimura E, Yamaji K, Nakashima K, Kashiwagi S (1996) IL-1β and TNF-α produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 41: 315-321
10. Kurokawa M, Imakita M, Kumeda, Cristina A, Yukawa Tomoyo A, Shiraki K (1996) Kakkon-to suppressed interleukin-1α production responsive to interferon and alleviated influenza infection in mice. J Trad Med 13: 201-209
11. Masuda N, Negoro S, Takeda K, Kurata N, Kuwabara T, Kobayashi S, Fukuoka M (1998) Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue. Br J Cancer 78: 388-389
12. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S (1995) Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346: 1051-1055
13. Ohno Y, Fujimoto M, Nishimura A, Aoki N (1998) Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)-β in patients with chronic hepatitis C. J Clin Endocrinol Metab 83: 3681-3687
14. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matsumura M, Narita T, Kawada K, Omata M (2000) High viral eradication with a daily 12-week natural interferon-β treatment regimen in chronic hepatitis C patients with low viral load. Dig Dis Sci 45: 2414-2421
15. Skoner DP, Gentile DA, Patel A, Doyle WJ (1999) Evidence for cytokine mediation for disease expression in adults experimentally infected with influenza A virus. J infect dis 180: 10-14
16. Soma M, Sasaki M, Sakamaki M, Tanaka S, Shimizu H, Kunihiro Y (2001) Post marketing surveillance of natural IFN-β preparation for chronic hepatitis C. Jpn J Pharmacoepidemiol 6: 5-28
17. Sondergaard SR, Ostrowski K, Ullum, H, Pedersen BK (2000) Changes in plasma concentration of interleukin-6 and interleukin-1 receptor antagonists in response to adrenaline infusion in humans. Eur J Appl Physiol 83: 95-98
18. Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshell L, Burger K, Fehm HL, Born J (1998) Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 83: 1573-1579
19. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW (1994) Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113-118
20. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131: 174-181